CN106754698A - A kind of method of separation and the activation for human peripheral T cell - Google Patents
A kind of method of separation and the activation for human peripheral T cell Download PDFInfo
- Publication number
- CN106754698A CN106754698A CN201611102195.6A CN201611102195A CN106754698A CN 106754698 A CN106754698 A CN 106754698A CN 201611102195 A CN201611102195 A CN 201611102195A CN 106754698 A CN106754698 A CN 106754698A
- Authority
- CN
- China
- Prior art keywords
- cell
- human peripheral
- activation
- antibody
- separation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of method of separation and the activation for human peripheral T cell, the method is that, using CD4 and CD8 antibody Beads enrichment human peripheral T cells, the T cell that then will be obtained is activated with t cell activation reagent, so as to be prepared for slow virus conversion.The method is comprised the following steps：With PMNC separating liquid separating peripheral blood mononuclear cells；By PMNC and CD4 and CD8 antibody magnetic bead hatching combinations；T cell after incubation is separated and obtains human peripheral T cell by the splitter being placed in magnetic field；The human peripheral T cell for obtaining will be separated to be suspended in T cell culture medium, add t cell activation reagent to enter line activating.The method is simple and easy to apply, reproducible, can simultaneously obtain CD4 and CD8 T cell of the purity higher than 90%, when the T cell of application expression CD19 and CD20 antibody gene Chimeric antigen receptors is treated, effectively ensures therapeutic effect.
Description
Technical field：
The present invention relates to cell sorting and cells in vitro activation technique field, and in particular to one kind is thin for human peripheral T
The separation of born of the same parents and the method for activation.
Background technology：
T lymphocytes are the key members for participating in immune response, to T lymphocyte phenotypes feature and its depth of function
Enter research, be of great importance in basic theory with clinical practice.Stabilization and efficiently separate high-purity and physiological function with
The impregnable T lymphocytes of structure are premise and the basis for carrying out a series of immunological investigations.
Julius etc. establishes a kind of method of quick separating T cell earliest：T cell surface is more smooth, and B cell surface
Fine hair is more, and the lymphocyte suspension of mixing is when by nylon hair post, and B cell, thick liquid cell, monocyte and some auxiliary are thin
Born of the same parents are selectively adhered on nylon hair, need to be taken off with cold wash and extruding nylon cotton method can just be obtained, and most T cells then pass through
Eluted on nylon Mao Zhucong nylon hair.Although easy to operation using the method that nylon hair separates T cell, without special
Instrument, it is small to cellular damage, it is useful in grass-roots unit, the experimental teaching of the clinical research work and student carried out.But separate
Purity only up to (48.3 ± 11.2) % of T cell is obtained, with the appearance of monoclonal antibody, in order to improve cell purification efficiency,
Cell (immune sorting, immune selection) is sorted with reference to other technologies using specific monoclonal antibody.Complementation cell poison
It with Lympho-kwik T is a kind of mix reagent of similar cocktail that method is, containing monoclonal antibody and complement, and can be formed close
Degree gradient, B cell and monocyte are removed by antigen-antibody complex complement activation.The method is simple and easy to apply, significantly contracting
It is short operating time, but the purity of obtained T cell is (82.8 ± 3.2) %, still not ideal enough, may with antibody multigelation,
Antibody after melting is not timely used causes antibody activity reduction relevant.Further to improve separating effect, immune magnetic is occurred in that
Pearl method, T cell is combined through the antibody-mediated magnetic micro-beads with diameter 50nm of CD2, and under high-intensity magnetic field, T cell is attracted and is detained
Selected in post in sun, after selecting post to remove magnetic field sun, then T cell is eluted, so can stable, quickly and efficiently isolated
T cell of the purity higher than 95%, is as a result substantially better than both the above method.But the magnetic bead antibody term of validity is shorter, need to make in time
With.Standing time antibody more long, when using can proper extension incubation time, can equally reach good separating effect, but incubate
Educating overlong time can cause the non-specific mark of non-target cell.Whether it has been activated by the T cell of Magnetic Isolation, sun selects T
Whether influence its Function detection still disputable after cell combination microballon.
The content of the invention：
In view of the shortcomings of the prior art, the present invention provides a kind of separation for human peripheral T cell and activation
Method.
The purpose of the present invention is achieved through the following technical solutions：
A kind of method of separation and activation for human peripheral T cell, the method is using CD4 and CD8 antibody magnetic beads
Human peripheral T cell is separated, the T cell that then will be obtained is activated with t cell activation reagent, so as to do standard for slow virus conversion
It is standby.
Above-mentioned utilization CD4 and CD8 antibody Beads enrichment human peripheral T cells are by human peripheral leucocytes and CD4 and CD8
Antibody magnetic bead is incubated altogether, in the splitter that then T cell after incubation is placed in magnetic field, it is combined with antibody magnetic bead, leads to
The effect in magnetic field is crossed, the negative cells not combined with antibody magnetic bead can wash out splitter with buffer solution；Combined with antibody magnetic bead
T cell be stranded in splitter, will be detained have T cell splitter be moved away from magnetic field, that is, separate obtain human peripheral T cell.
Above-mentioned t cell activation reagent using TransAct CD3/28, TransAct CD3/28 be by the CD3 of humanization and
CD28 antibody couplings and the nanomatrix being polymerized, can advantageously be removed by centrifugation, and the cell after being activated through the reagent can be effective
Converted by slow virus.
Further, the present invention is comprised the following steps for the method for separation and the activation of human peripheral T cell：
S1：With PMNC separating liquid Ficoll-Paque separating peripheral blood mononuclear cells；
S2：By PMNC and CD4 and CD8 antibody magnetic bead hatching combinations；
S3：T cell after incubation is separated and obtains human peripheral T cell by the splitter being placed in magnetic field；
S4：The human peripheral T cell for obtaining will be separated and be suspended in T cell culture medium C TSTM OpTmizerTM
(ThermoFisher Scientific), adds t cell activation reagent TransAct CD3/28 (Miltenyi Biotech)
Enter line activating.
CD4 and cd8 t cell can simultaneously be obtained for the method for separation and the activation of human peripheral T cell by the present invention,
For the T cell of production expression CD19 and CD20 antibody gene Chimeric antigen receptors provides guarantor containing CD4 and cd8 t cell simultaneously
Card, therefore, when the T cell of application expression CD19 and CD20 antibody gene Chimeric antigen receptors is treated, CD4 is contained simultaneously
Can effectively ensure therapeutic effect with cd8 t cell.
The present invention is simple and easy to apply for the method for separation and the activation of human peripheral T cell, reproducible, can obtain purity
T cell higher than 90%.
Specific embodiment：
Technical scheme is further described below, but is not limited thereto, it is every to the technology of the present invention
Scheme is modified or equivalent, without deviating from the spirit and scope of technical solution of the present invention, all should be covered in the present invention
Protection domain in.
The present invention is comprised the following steps for the method for separation and the activation of human peripheral T cell：
(1) peripheral blood is made into 5X volume dilutions with the phosphate buffer of pH7.2；
(2) 15mL PMNC separating liquids Ficoll-Paque is added in 50mL centrifuge tubes；
(3) lentamente the peripheral blood after dilution is successively added on Ficoll-Paque, room temperature centrifugation 400g, 30min；
(4) upper plasma is carefully sucked, is careful not to stir middle mononuclearcell layer；
(5) lightly intermediate layer is transferred in new 50mL centrifuge tubes, phosphate is then added in the centrifuge tube and is delayed
Supernatant is abandoned in fliud flushing to 50mL, room temperature centrifugation 300g, 10min, shifting；
(6) cell precipitation is suspended in 50mL phosphate buffers, supernatant is abandoned in room temperature centrifugation 200g, 10min, shifting；
(7) repeat step (6), to remove most of blood platelet, the white eggs of human blood of 50mL 0.5% are suspended in by cell precipitation
In in vain/PBS/EDTA buffer solutions；
(8) a small amount of cell count is taken, with the content of CD4 and cd8 cell component in flow cytometry analysis mononuclearcell；
(9) cell room temperature is centrifuged 300g, 10min, supernatant is abandoned in shifting；
(10) according to 80 μ L/107Cell precipitation is suspended in the white egg of 0.5% human blood by the volume of total PMNC
In in vain/PBS/EDTA buffer solutions；
(11) according to 40 μ L/107In PMNC CD4 and cd8 cell component amount add the micro- magnetic beads of CD4 and
The micro- magnetic beads of CD8 (the micro- magnetic beads of CliniMACS CD4 and CD8)；
(12) it is well mixed, puts room temperature rotation and be incubated 30min；
(13) according to 2mL/107The volume of total PMNC adds 0.5% human serum albumin/PBS/EDTA to delay
Supernatant is abandoned in fliud flushing, room temperature centrifugation 300g, 10min, shifting；
(14) according to 500 μ L/108It is white that cell precipitation is suspended in 0.5% human blood by the volume of total PMNC
In albumen/PBS/EDTA buffer solutions；
(15) MACS LS splitters are placed in MACS separator magnets, it is slow with 0.5% human serum albumin/PBS/EDTA
Fliud flushing 3mL is rinsed；
(16) the PMNC suspension being incubated with magnetic bead is added on splitter (depending on cell number to be separated
The multiple splitters of selection, LS splitter maximum separations load capacity is 108Positive cell/splitter), the cell for collecting outflow hangs
Liquid；
(17) rinse splitter three times with 0.5% human serum albumin/PBS/EDTA buffer solutions 3mL, collect the cell of outflow
Suspension, the mixing with cells collected with step (16) is CD4 and CD8 negative cells components；
(18) splitter is moved away from into separator magnet to be placed on a collecting pipe, adds 0.5% human serum albumin/PBS/
Edta buffer liquid 5mL, and immediately will be trapped in positive cell in splitter with piston and release, this cellular component be CD4 and
CD8 positive T cells；
(19) a small amount of cell count is taken, with containing for CD4 in flow cytometry analysis mononuclearcell and cd8 cell component
Amount, assesses separating effect；
(20) CD4 the and CD8 positive T cells room temperature that will be obtained is centrifuged 300g, 10min, and supernatant is abandoned in shifting；
(21) cell precipitation is suspended in the OpTmizer containing 2% human serum AB and is washed, room temperature centrifugation 300g, 10min,
Supernatant is abandoned in shifting；
(22) according to 1X06Be suspended in cell precipitation containing 2% human serum AB by/mL cell concentrations, and 200 units/mL cells are situated between
In the T cell culture medium of -2 (IL-2) of element, according to 1:17.5 dilution factors add TransActCD3/28T cell activators；
(23) cell is transferred in T75 blake bottles, is placed in 37 DEG C, 5%CO2Cultivated in incubator.
Separated simultaneously by the above method and obtain CD4 and CD8 positive T cells, its result such as table 1 below：
As shown in Table 1：The purity that the method separates CD4 the and CD8 positive T cells for obtaining is 92.8%, and the rate of recovery is
60.7%, therefore, enter using the T cell containing CD4 and cd8 t cell expression CD19 and CD20 antibody gene Chimeric antigen receptors
During row treatment, can effectively ensure therapeutic effect.
Claims (7)
1. a kind of method of separation and activation for human peripheral T cell, it is characterised in that：Methods described be using CD4 and
CD8 antibody Beads enrichment human peripheral T cells, the T cell that then will be obtained is activated with t cell activation reagent, so that for slow
Virus Transformation is prepared.
2. the method for separation and the activation for human peripheral T cell according to claim 1, it is characterised in that：It is described
It is to incubate human peripheral leucocytes altogether with CD4 and CD8 antibody magnetic beads using CD4 and CD8 antibody Beads enrichment human peripheral T cells
Educate, in the splitter that then T cell after incubation is placed in magnetic field, it is combined with antibody magnetic bead, by the effect in magnetic field,
The negative cells not combined with antibody magnetic bead can wash out splitter with buffer solution；The T cell combined with antibody magnetic bead is stranded in
In splitter, the splitter that will be detained has T cell is moved away from magnetic field, that is, separate and obtain human peripheral T cell.
3. the method for separation and the activation for human peripheral T cell according to claim 1, it is characterised in that：The T
Cell-stimulating reagent uses TransAct CD3/28, and it is by CD3 the and CD28 antibody couplings of humanization and the nanometer base being polymerized
Matter, can advantageously be removed by centrifugation, and the cell after being activated through the reagent can be converted effectively by slow virus.
4. the side of separation and the activation for human peripheral T cell according to claims 1 to 3 any one claim
Method, it is characterised in that：The method of separation and the activation for human peripheral T cell, comprises the following steps：
S1：With PMNC separating liquid separating peripheral blood mononuclear cells；
S2：By PMNC and CD4 and CD8 antibody magnetic bead hatching combinations；
S3：T cell after incubation is separated and obtains human peripheral T cell by the splitter being placed in magnetic field；
S4：The human peripheral T cell for obtaining will be separated to be suspended in T cell culture medium, t cell activation reagent TransAct is added
CD3/28 enters line activating.
5. the method for separation and the activation for human peripheral T cell according to claim 4, it is characterised in that：It is described
PMNC separating liquid uses PMNC separating liquid Ficoll-Paque.
6. the method for separation and the activation for human peripheral T cell according to claim 4, it is characterised in that：The T
Cell culture medium is the T cell culture medium containing 2% human serum AB and 200 units/mL cytokine -2s.
7. the method for separation and the activation for human peripheral T cell according to claim 4, it is characterised in that：The T
The addition of cell-stimulating reagent TransAct CD3/28 presses 1:17.5 dilution factors are added.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611102195.6A CN106754698A (en) | 2016-12-05 | 2016-12-05 | A kind of method of separation and the activation for human peripheral T cell |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611102195.6A CN106754698A (en) | 2016-12-05 | 2016-12-05 | A kind of method of separation and the activation for human peripheral T cell |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106754698A true CN106754698A (en) | 2017-05-31 |
Family
ID=58883550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611102195.6A Pending CN106754698A (en) | 2016-12-05 | 2016-12-05 | A kind of method of separation and the activation for human peripheral T cell |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106754698A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111621477A (en) * | 2020-05-25 | 2020-09-04 | 合源生物科技(天津)有限公司 | T cell sorting method |
| CN116893265A (en) * | 2023-09-08 | 2023-10-17 | 军科正源（北京）药物研究有限责任公司 | Method and kit for detecting protein phosphorylation in PBMC and related applications |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101570739A (en) * | 2009-06-05 | 2009-11-04 | 刘晓明 | Method for building psoriasis basic research models, and gas-liquid level transmembrane device |
| CN102321580A (en) * | 2011-08-23 | 2012-01-18 | 郑颂国 | Regulatory T cells for treating autoimmune diseases, and preparation method thereof |
| CN103800898A (en) * | 2014-03-13 | 2014-05-21 | 蔡颖 | Tumor specific killer cell preparation and preparation method thereof |
| CN105670993A (en) * | 2016-04-22 | 2016-06-15 | 福州创方医药科技有限公司 | Integrated T cell culture and extraction method |
| CN106062185A (en) * | 2014-04-24 | 2016-10-26 | 美天旎生物技术有限公司 | Method for automated generation of genetically modified t cells |
-
2016
- 2016-12-05 CN CN201611102195.6A patent/CN106754698A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101570739A (en) * | 2009-06-05 | 2009-11-04 | 刘晓明 | Method for building psoriasis basic research models, and gas-liquid level transmembrane device |
| CN102321580A (en) * | 2011-08-23 | 2012-01-18 | 郑颂国 | Regulatory T cells for treating autoimmune diseases, and preparation method thereof |
| CN103800898A (en) * | 2014-03-13 | 2014-05-21 | 蔡颖 | Tumor specific killer cell preparation and preparation method thereof |
| CN106062185A (en) * | 2014-04-24 | 2016-10-26 | 美天旎生物技术有限公司 | Method for automated generation of genetically modified t cells |
| CN105670993A (en) * | 2016-04-22 | 2016-06-15 | 福州创方医药科技有限公司 | Integrated T cell culture and extraction method |
Non-Patent Citations (3)
| Title |
|---|
| ISETT LAUX等: "Response Differences between Human CD41 and CD81 T-Cells during CD28 Costimulation: Implications for Immune Cell-Based Therapies and Studies Related to the Expansion of Double-Positive T-Cells during Aging", 《CLINICAL IMMUNOLOGY》 * |
| 李英等: "咳喘宁对病毒诱发哮喘模型大鼠CD4+、CD8+T 细胞内信号转导子和转录激活子6 表达的影响", 《中国中医药信息杂志》 * |
| 马静等: "可溶性DC-SIGN对T淋巴细胞增殖及分泌细胞因子的调节作用", 《细胞与分子免疫学杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111621477A (en) * | 2020-05-25 | 2020-09-04 | 合源生物科技(天津)有限公司 | T cell sorting method |
| CN111621477B (en) * | 2020-05-25 | 2021-06-22 | 合源生物科技(天津)有限公司 | T cell sorting method |
| WO2021238924A1 (en) * | 2020-05-25 | 2021-12-02 | 合源生物科技(天津)有限公司 | Method for sorting t cells |
| CN116893265A (en) * | 2023-09-08 | 2023-10-17 | 军科正源（北京）药物研究有限责任公司 | Method and kit for detecting protein phosphorylation in PBMC and related applications |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1324100C (en) | Multiple stage affinity process for isolation of specific cells from a cell mixture | |
| CN105734043B (en) | Multi-sort cell separation method | |
| CN102719398A (en) | Novel efficient method for separating human T-Lymphocytes by immunomagnetic beads | |
| de Masson et al. | Purification and immunophenotypic characterization of human B cells with regulatory functions | |
| Pierzchalski et al. | An innovative cascade system for simultaneous separation of multiple cell types | |
| CN106754698A (en) | A kind of method of separation and the activation for human peripheral T cell | |
| Cui et al. | Isolation of polymorphonuclear neutrophils and monocytes from a single sample of human peripheral blood | |
| KR101533230B1 (en) | Multistage microfluidic chip and method for selective isolation of sample using the same | |
| Sekine et al. | Panning of multiple subsets of leukocytes on antibody-decorated poly (ethylene) glycol-coated glass slides | |
| CN106969964B (en) | Negative phase enrichment method and kit for rare cells in blood based on micro-fluidic and immunomagnetic separation | |
| Payne et al. | Evaluation of surface markers on normal human lymphocytes containing parallel tubular arrays: a quantitative ultrastructural study | |
| Tong et al. | A novel high throughput immunomagnetic cell sorting system for potential clinical scale depletion of T cells for allogeneic stem cell transplantation | |
| Pilling et al. | The kinetics of interaction between lymphocytes and magnetic polymer particles | |
| JP2013501924A (en) | Method for separating particles and / or cells having two or more surface properties | |
| Petitjean et al. | Isolation and characterization of HIV-1-infected resting CD4+ T lymphocytes in breast milk | |
| Tsang et al. | Simplified purification of human basophils | |
| JPH11502106A (en) | Methods for enriching small cell populations | |
| Heine et al. | Isolation of human B cell populations | |
| Akuthota et al. | Eosinophil purification from peripheral blood | |
| CN105505874B (en) | It a kind of modulability macrophage of people's derived from cord blood and its isolates and purifies and cultural method | |
| Baran et al. | Cell sorting using a universally applicable affinity chromatography matrix: solid-phase anti-fluorescein isothiocyanate antibody | |
| CN102329774A (en) | Method for isolating monocytes in bovine peripheral blood | |
| Brinchmann et al. | Quantification of lymphocyte subsets based on positive immunomagnetic selection of cells directly from blood | |
| Kovithavongs et al. | Serotyping for MLG Gene Products: I. Presumptive Evidence that ABGIL* may Detect MLG Factors | |
| CN101659939A (en) | Monocyte separating method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170531 |